Sunitinib in Metastatic Renal Cell Carcinoma: Clinical Outcomes Across Risk Groups in a Turkish Oncology Group Kidney Cancer Consortium
| dc.contributor.author | Bolek, Hatice | |
| dc.contributor.author | Kuzu, Omer Faruk | |
| dc.contributor.author | Sertesen Camoz, Elif | |
| dc.contributor.author | Sim, Saadet | |
| dc.contributor.author | Sekmek, Serhat | |
| dc.contributor.author | Karakas, Hilal | |
| dc.contributor.author | Urun, Yuksel | |
| dc.date.accessioned | 2025-02-25T19:32:16Z | |
| dc.date.available | 2025-02-25T19:32:16Z | |
| dc.date.issued | 2025 | |
| dc.description | Sertesen Camoz, Elif/0000-0002-1991-6620; Guliyev, Murad/0000-0002-2981-8098; Yekeduz, Emre/0000-0001-6819-5930 | en_US |
| dc.description.sponsorship | Turkish Oncology Group Kidney Cancer Consortium; Pfizer | en_US |
| dc.description.sponsorship | We would like to express our deepest gratitude to all the contributors of the Turkish Oncology Group Kidney Cancer Consortium (TKCC) for their invaluable support throughout this study. Special thanks to Ozlem Ustundag for her exceptional administrative support and assistance in data compilation. This study was sponsored by Pfizer. | en_US |
| dc.identifier.doi | 10.1002/cac2.70003 | |
| dc.identifier.issn | 2523-3548 | |
| dc.identifier.scopus | 2-s2.0-85217359773 | |
| dc.identifier.uri | https://doi.org/10.1002/cac2.70003 | |
| dc.identifier.uri | https://hdl.handle.net/20.500.14365/5965 | |
| dc.language.iso | en | en_US |
| dc.publisher | Wiley | en_US |
| dc.relation.ispartof | Cancer Communications | en_US |
| dc.rights | info:eu-repo/semantics/openAccess | en_US |
| dc.title | Sunitinib in Metastatic Renal Cell Carcinoma: Clinical Outcomes Across Risk Groups in a Turkish Oncology Group Kidney Cancer Consortium | en_US |
| dc.type | Letter | en_US |
| dspace.entity.type | Publication | |
| gdc.author.id | Sertesen Camoz, Elif/0000-0002-1991-6620 | |
| gdc.author.id | Guli̇yev, Murad/0000-0002-2981-8098 | |
| gdc.author.id | Yekeduz, Emre/0000-0001-6819-5930 | |
| gdc.author.wosid | Guliyev, Murad/Jgm-6815-2023 | |
| gdc.author.wosid | Kuzu, Omer/Mit-0739-2025 | |
| gdc.author.wosid | Sever, Özlem Nuray/Kzu-7347-2024 | |
| gdc.author.wosid | Sertesen, Elif/Kjm-8461-2024 | |
| gdc.author.wosid | Yekeduz, Emre/Aba-5814-2020 | |
| gdc.author.wosid | Sekmek, Serhat/Jjc-1990-2023 | |
| gdc.bip.impulseclass | C5 | |
| gdc.bip.influenceclass | C5 | |
| gdc.bip.popularityclass | C5 | |
| gdc.coar.access | open access | |
| gdc.coar.type | text::letter | |
| gdc.collaboration.industrial | false | |
| gdc.description.department | İzmir Ekonomi Üniversitesi | en_US |
| gdc.description.departmenttemp | [Bolek, Hatice; Urun, Yuksel] Ankara Univ, Sch Med, Dept Med Oncol, TR-06590 Ankara, Turkiye; [Bolek, Hatice; Urun, Yuksel] Ankara Univ, Canc Res Inst, Ankara, Turkiye; [Kuzu, Omer Faruk; Karadurmus, Nuri] Univ Hlth Sci, Gulhane Training & Res Hosp, Dept Med Oncol, Ankara, Turkiye; [Sertesen Camoz, Elif; Karacin, Cengiz] Univ Hlth Sci, Dr Abdurrahman Yurtaslan Oncol Training Res Hosp, Dept Med Oncol, Ankara, Turkiye; [Sim, Saadet] Ege Univ, Sch Med, Dept Med Oncol, Izmir, Turkiye; [Sekmek, Serhat; Karakas, Hilal; Sendur, Mehmet Ali Nahit] Ankara Bilkent City Hosp, Dept Med Oncol, Ankara, Turkiye; [Isik, Selver] Marmara Univ Sch Med, Dept Med Oncol, Istanbul, Turkiye; [Guliyev, Murad] Cerrahpasa Med Sch, Dept Med Oncol, Istanbul, Turkiye; [Akkus, Aysun Fatma] Trakya Univ, Sch Med, Dept Med Oncol, Edirne, Turkiye; [Tural, Deniz] Univ Hlth Sci, Bakirkoy Dr Sadi Konuk Training & Res Hosp, Dept Med Oncol, Istanbul, Turkiye; [Arslan, Cagatay] Izmir Univ Econ, Med Point Hosp, Izmir, Turkiye; [Goksu, Sema Sezin] Akdeniz Univ, Sch Med, Dept Med Oncol, Antalya, Turkiye; [Sever, Ozlem Nuray] Kartal Dr Lutfi Kirdar City Hosp, Dept Ophthalmol, Istanbul, Turkiye; [Yekeduez, Emre] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA USA | en_US |
| gdc.description.endpage | 576 | |
| gdc.description.endpage | 576 | en_US |
| gdc.description.issue | 5 | en_US |
| gdc.description.publicationcategory | Diğer | en_US |
| gdc.description.scopusquality | Q1 | |
| gdc.description.startpage | 572 | |
| gdc.description.startpage | 572 | en_US |
| gdc.description.volume | 45 | |
| gdc.description.volume | 45 | en_US |
| gdc.description.woscitationindex | Science Citation Index Expanded | |
| gdc.description.wosquality | Q1 | |
| gdc.identifier.openalex | W4407348534 | |
| gdc.identifier.pmid | 39927571 | |
| gdc.identifier.wos | WOS:001420774000001 | |
| gdc.index.type | WoS | |
| gdc.index.type | Scopus | |
| gdc.index.type | PubMed | |
| gdc.oaire.accesstype | GOLD | |
| gdc.oaire.diamondjournal | false | |
| gdc.oaire.impulse | 1.0 | |
| gdc.oaire.influence | 2.5000004E-9 | |
| gdc.oaire.isgreen | true | |
| gdc.oaire.keywords | Neoplasms. Tumors. Oncology. Including cancer and carcinogens | |
| gdc.oaire.keywords | RC254-282 | |
| gdc.oaire.keywords | Letter to the Journal | |
| gdc.oaire.popularity | 3.5043568E-9 | |
| gdc.oaire.publicfunded | false | |
| gdc.openalex.collaboration | International | |
| gdc.openalex.fwci | 1.6817 | |
| gdc.openalex.normalizedpercentile | 0.79 | |
| gdc.openalex.toppercent | TOP 10% | |
| gdc.opencitations.count | 0 | |
| gdc.plumx.crossrefcites | 1 | |
| gdc.plumx.mendeley | 1 | |
| gdc.plumx.pubmedcites | 1 | |
| gdc.plumx.scopuscites | 1 | |
| gdc.scopus.citedcount | 1 | |
| gdc.wos.citedcount | 1 | |
| relation.isOrgUnitOfPublication | e9e77e3e-bc94-40a7-9b24-b807b2cd0319 | |
| relation.isOrgUnitOfPublication.latestForDiscovery | e9e77e3e-bc94-40a7-9b24-b807b2cd0319 |